(Q38002447)

26 August 2017

title

Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia (English)

1 reference

26 August 2017

1 reference

Xavier Thomas

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

16 April 2012

1 reference

Expert Opinion on Investigational Drugs

26 August 2017

published in

1 reference

26 August 2017

volume

21

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

871-878

1 reference

26 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November, 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Modern therapy of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Novel antibody-based therapies for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Cleavage behavior of calicheamicin gamma 1 and calicheamicin T

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Inotuzumab ozogamicin as novel therapy in lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Salvage therapy for refractory or relapsed acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

A Theoretical Model of γ-Globulin Catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.679359

10.1517/13543784.2012.679359

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference